Vera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
&-
All right. Let's go ahead and get started. Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad Priyanka Grover, [Laurea Hall], and Malcolm Kuno. Our next presenting company is Vera. And presenting on behalf of the company, we have their CEO, Marshall Fordyce. Marshall?
Great. Thanks, Anupam. Good afternoon and welcome, I'm Dr. Marshall Fordyce. I'm the founder and CEO of Vera Therapeutics. We're a clinical-stage biotech company developing treatments for serious immunologic diseases. Our mission is to change standard of care for patients, and I'm thrilled to share our substantial progress with you today.
Our lead clinical product candidate is atacicept, a first in class next-generation B-cell modulator currently in Phase 3 for patients with IgA nephropathy or IgAN. IgAN is a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |